Rep. Jefferson Shreve Sells Off Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Representative Jefferson Shreve (R-Indiana) recently sold shares of Gilead Sciences, Inc. NASDAQ: GILD. In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $15,001 and $50,000 in Gilead Sciences stock on May 12th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Hubbell NYSE: HUBB on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Trane Technologies NYSE: TT on 5/12/2025.
• Sold $15,001 - $50,000 in shares of RTX NYSE: RTX on 5/12/2025.
• Sold $50,001 - $100,000 in shares of NiSource NYSE: NI on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Johnson & Johnson NYSE: JNJ on 5/12/2025.
• Sold $15,001 - $50,000 in shares of AppLovin NASDAQ: APP on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Fiserv NYSE: FI on 5/12/2025.
• Sold $15,001 - $50,000 in shares of CNO Financial Group NYSE: CNO on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Cboe Global Markets NASDAQ: CBOE on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 5/12/2025.

Gilead Sciences Stock Up 2.7%

NASDAQ GILD traded up $3.00 during midday trading on Friday, hitting $116.20. 7,677,220 shares of the company traded hands, compared to its average volume of 5,825,949. Gilead Sciences, Inc. has a 52 week low of $72.43 and a 52 week high of $119.96. The company's 50-day simple moving average is $109.91 and its 200-day simple moving average is $105.88. The company has a market cap of $144.54 billion, a PE ratio of 24.46, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm's revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter last year, the company earned ($1.32) earnings per share. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Insider Activity

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction on Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the completion of the transaction, the chief executive officer directly owned 615,725 shares in the company, valued at $68,006,826.25. The trade was a 1.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total transaction of $277,575.00. Following the sale, the chief financial officer owned 162,610 shares in the company, valued at approximately $18,054,588.30. This represents a 1.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold 72,000 shares of company stock valued at $7,844,775 in the last quarter. Company insiders own 0.27% of the company's stock.

Institutional Investors Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GILD. NorthRock Partners LLC boosted its stake in shares of Gilead Sciences by 11.1% in the second quarter. NorthRock Partners LLC now owns 12,922 shares of the biopharmaceutical company's stock worth $1,433,000 after buying an additional 1,290 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in Gilead Sciences by 0.5% in the second quarter. Oregon Public Employees Retirement Fund now owns 107,541 shares of the biopharmaceutical company's stock valued at $11,923,000 after acquiring an additional 500 shares during the period. Vest Financial LLC lifted its holdings in Gilead Sciences by 39.3% in the second quarter. Vest Financial LLC now owns 14,472 shares of the biopharmaceutical company's stock valued at $1,605,000 after acquiring an additional 4,080 shares during the period. Welch Group LLC boosted its position in Gilead Sciences by 29.1% in the 2nd quarter. Welch Group LLC now owns 3,883 shares of the biopharmaceutical company's stock worth $431,000 after purchasing an additional 876 shares in the last quarter. Finally, Cypress Capital Group grew its stake in shares of Gilead Sciences by 1.1% during the 2nd quarter. Cypress Capital Group now owns 48,533 shares of the biopharmaceutical company's stock worth $5,381,000 after purchasing an additional 551 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent analyst reports. Oppenheimer lowered their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Morgan Stanley raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research report on Friday. Finally, Cantor Fitzgerald assumed coverage on Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective for the company. Eight analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average price target of $112.36.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.